An Epidemiological Study of Acute Coronary Syndromes in The Greek Population. The TARGET Study
Completed
- Conditions
- Acute Coronary Syndromes
- Registration Number
- NCT01061086
- Lead Sponsor
- AstraZeneca
- Brief Summary
This is a multicenter, 2-phase observational study of acute coronary syndromes (ACS) in Greece, designed to provide real world data on the risk factors of patients presenting to a hospital emergency department with an index event, as well as to depict the current management practices and outcomes of these clinical conditions in Greece.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 418
Inclusion Criteria
- Diagnosis of an ACS (STEMI, NSTEMI, UA).
- Informed Consent
Exclusion Criteria
- Involvement in the planning and conduct of the study (applies to both AstraZeneca staff and staff at the study sites).
- Participation in other clinical study in period between the index event and 6- month follow-up assessment with the exception of registering in registries or surveys not influencing the management of the ACS.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To evaluate the proportion of patients who are on target for LDL-C according to the 2004-updated NCEP ATPIII guidelines as calculated within the first 24-hours of hospital admission for an ACS. first visit - 1st day (cross-sectional part) To estimate the proportion of patients enrolled in the cross-sectional part of the study that experiences a Major Adverse Cardiovascular Event (MACE) within a 6-month follow-up period. follow up visit - 6th month (prospective part)
- Secondary Outcome Measures
Name Time Method To estimate the proportion of patients admitted to the hospital with STEMI, NSTEMI and unstable angina. first visit - 1st day (cross-sectional part) To estimate the "pain-to-door-time" throughout different regions in Greece. first visit - 1st day (cross-sectional part) To estimate the time to first MACE and to estimate CV, non-CV and all cause mortality within the 6-month period following the index ACS event. follow up visit - 6th month (prospective part)
Trial Locations
- Locations (1)
Research Site
🇬🇷Chios, Greece